GlassScriptPhysician profile
Andrew Judah Green
NPI 1255325791
$322,471.06
in general payments reported to CMS, 2019-2025
42 companies · $56.97 in 2025
The $56.97 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $58K · 2021: $55K · 2022: $57K · 2023: $17K · 2024: $16K · 2025: $56.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $1,652 · Travel and Lodging: $369 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,200.00 |
| Food and Beverage | $1,651.83 |
| Travel and Lodging | $368.52 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198,549.76 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53,083.71 | 2019-2023 | Jardiance, Synjardy |
| Lilly USA, LLC | $42,688.73 | 2019-2024 | Jardiance, Mounjaro, Humulin |
| Abbvie INC. | $11,581.73 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $7,161.16 | 2019-2020 | |
| Mannkind Corporation | $5,050.25 | 2022 | |
| Abbott Laboratories | $576.08 | 2021-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $418.08 | 2019-2023 | Farxiga |
| Pfizer INC. | $340.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $300.67 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $288.55 | 2019-2023 | Steglujan, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $274.20 | 2022-2023 | |
| Insulet Corporation | $258.83 | 2019-2024 | Omnipod |
| Corcept Therapeutics | $255.93 | 2022-2023 | Korlym |
| Radius Health, INC. | $222.18 | 2019-2023 | Tymlos |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.